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Most medical treatments of Parkinson’s disease (PD) are aimed at the reduction of motor 
symptoms. However, even when motor improvements are evident, patients often report a 
deterioration of their daily lives. Thus, to achieve a global improvement in personal well-
being,  not  only  drugs,  but  also  complementary  therapies,  such  as  physical  exercise, 
occupational therapy, speech therapy, and active music therapy, have been used. We 
hypothesized that theater could reduce clinical disability and improve the quality of life 
of PD patients (primary end points) more efficiently than other complementary therapies 
because (1) in order to impersonate a character, patients are forced to regain the control 
of their bodies; and (2) while being part of a group, patients have a high degree of social 
interaction. The need to regain the control of their bodies and of their social functioning 
is  very  likely  to  deeply  motivate  patients.  To  assess  this  hypothesis,  we  ran  a 
randomized,  controlled,  and  single-blinded  study  that  lasted  3  years,  on  20  subjects 
affected by a moderate form of idiopathic PD, in stable treatment with L-dopa and L-dopa 
agonists, and without severe sensory deficits. Ten patients were randomly assigned to 
an  active  theater  program  (in  which  patients  were  required  to  participate),  while  the 
others underwent physiotherapy (control group), the most common nonpharmacological 
treatment for PD rehabilitation. Patients of both groups were evaluated at the beginning 
of each year, using five clinical rating scales (Unified Parkinson’s Disease Rating Scale 
[UPDRS], Schwab and England Scale, Parkinson’s Disease Quality of Life [PDQ39] Scale, 
Epworth Sleepiness Scale, and Hamilton Depression Rating Scale). The theater patients 
showed  progressive  improvements  and,  at  the  end  of  the  third  year,  they  showed 
significant improvements in all clinical scales. Conversely, the control patients did not 
exhibit  significant  ameliorations  with  time.  Thus,  the  present  study  provides  the  first 
scientific  evidence  that  active  theater,  coupled  with  conventional  medical  treatments, 
represents a valid complementary therapeutic intervention for PD treatment.  
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INTRODUCTION  
Parkinson‟s disease (PD) is a neurodegenerative disease that causes motor disturbances (postural and 
walking  difficulties,  rigidity,  bradykinesia,  and  tremor)  and  nonmotor  disturbances,  such  as 
neuropsychiatric (e.g., depression, anxiety, cognitive impairments) and neurovegetative disorders (e.g., 
decreased control of urinary bladder, sexual dysfunctions; for review see [1]). Consequently, general 
health and the personal and social lives of patients can be deeply impaired.  
Pharmacological treatment of PD, based on the administration of dopaminergic drugs, is symptomatic 
and mainly aimed at reducing motor symptoms. With this approach, optimal control of the symptoms is 
possible only in the initial stages of PD. With time, however, the positive effects become less evident, 
nonmotor symptoms progressively increase, side effects of the dopaminergic medications appear, and the 
management of the disease becomes more complex[2]. Often with the progression of the disease, PD 
patients experience trouble with communication and this may lead to social isolation as the person may be 
embarrassed by the disease (Scottish Intercollegiate Guidelines Network 2010,  http://www.sign.ac.uk/ 
index.html). As a consequence, patients start to suffer from a deterioration of their social functioning and 
their quality of life (QoL).  
For these reasons, in addition to pharmacological treatments, complementary approaches have been 
tested.  Most  of  patients  undergo  physiotherapy[3]  and  this  intervention  has  been  shown  to  be 
effective[4,5,6]. However, improvements do not always outlast the treatment[7,8] and do not always help 
to manage nonmotor symptoms, probably because physiotherapy is usually lacking in the motivational 
and emotional spheres. 
Other  complementary  therapies,  such  as  group  psychotherapy[9],  art  therapies[10,11],  and 
occupational therapies[12], have been shown to produce positive effects on QoL. These complementary 
therapies do not offer a cure for PD, but may help to ease the symptoms and make coping with the disease 
easier. In fact, complementary therapies address not only the physical aspect of PD pathology, they also 
tackle its social and psychological aspects. Despite this potentiality, there are few randomized controlled 
trials testing their efficacy[13]. Among those, Pacchetti et al.[11] showed for the first time that 3 months 
of active music therapy, where PD patients play an active part by using instruments and voices, improve 
both their motor abilities and emotional status. They attributed the improvements of motor performance, 
especially of bradykinesia, to the rhythmic aspect of music and to its affective arousal, which was thought 
to be also at the basis of ameliorations of emotional functions. Pacchetti et al.[11] concluded, suggesting 
that by promoting socialization, expression of feelings, awareness, and responsiveness, music therapy 
increases motivation in patients whose personalities are frequently characterized by apathy, anhedonia, 
and depressive symptoms. However, these changes were not stable. In fact, even though improvements in 
motor response occurred after each music therapy session, only the changes in bradykinesia showed a 
trend  of  improvement  across  the  overall  evaluation.  Improvements  in  emotional  functions  were  also 
evident  after  each  session  and  at  the  end  of  the  study.  It  is  important  to  note  that  both  motor  and 
emotional changes disappeared 2 months after completion of the therapy. 
We hypothesized that active theater, which shares some features with active music therapy (e.g., the 
combination of movements and stimulation of different sensory pathways, emotional involvement), might 
have a stronger effect than music because of the special features required by this discipline. In order to be 
able to impersonate a character, patients need to control their bodies and minds carefully. In other words, 
patients have to be aware of and control each movement they produce and, at the same time, they also 
have to represent their character‟s emotions, i.e., they need to be able to feel and reproduce  his/her 
feelings. In addition, both during the performance and off the set, patients have to interact continuously, 
so they are forced to socialize. The strict coupling between motor control and ability to manage social 
situations makes theater an ideal playground to motivate patients deeply. In turn, this might allow a more 
stable improvement of clinical disability and QoL (primary end points) of PD patients. We compared the 
effect of theater therapy with physiotherapy, the most common among the nonpharmacological treatments 
for PD[3]. Modugno et al.: Theater, Rehabilitation, and Parkinson’s Disease  TheScientificWorldJOURNAL (2010) 10, 2301–2313 
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MATERIALS AND METHODS  
Subjects 
We selected 24 patients from the outpatients of the Parkinson‟s unit of IRCCS Neuromed Hospital (Italy). 
Criteria for including PD patients were: (1) being affected by a moderate form of idiopathic PD (Hoehn & 
Yahr stage 2–4), (2) being in stable treatment with L-dopa and L-dopa agonists, (3) not having severe 
sensory (visual or auditory) deficits, and (4) not having severe movement dysfunctions.  
Throughout  the  entire  course  of  the  study,  patients  were  allowed  to  continue  taking  their 
dopaminergic therapy, consisting of L-dopa alone or in association with dopamine agonists. Whenever 
necessary, the drug therapies were modified and optimized according to the patient‟s clinical progress. 
The assumption of antidepressant or hypnotic agents was not systematically controlled, but at the end of 
the study, they were equally distributed between the two groups.   
Twelve patients were randomly assigned to a theater workshop rehabilitation program (theater group), 
while the other 12 underwent a standard rehabilitation therapy based on physiotherapy (control group). To 
assign a patient to a group, we adopted the following procedure. First, we matched patients two by two for 
age, sex, years from the PD diagnosis, and pharmacological treatments in the best possible way. Second, 
exploiting a computer routine implemented in MATLAB (The Mathworks, Inc., Natick, MA), we randomly 
assigned one member of the 12 pairs to one group. Importantly, patients knew that they were taking part in a 
study but, in order to prevent complaints, we did not tell to the people of one group what the other group 
was experiencing. None of the patients of the two groups refused to participate.  
All subjects gave their informed consent and were free to withdraw from the study at any time. The 
general procedures were approved by the local Institutional Ethics Committee and were performed in 
accordance with the ethical standards laid down in the Declaration of Helsinki of 1964. 
Clinical Assessment 
For the entire period of the experiment, 3 years, all patients were monitored twice a month. Four patients 
(two from the theater group and two from the control group) did not conclude the study because of 
logistic problems (they changed their home towns following their families). Two patients left the study 
during the first year and the other two after the second year. Their data are not included in the present 
study in order to allow the use of repeated-measures designs, but they were in line with those presented in 
the paper.  
On average, the remaining patients of both groups took part in at least 70–80% of the rehabilitation 
sessions. All patients underwent a clinical evaluation at the beginning of the monitoring period (T0), after 
1 year (T1), 2 years (T2), and 3 years (T3). A neurologist (NM) blinded to the study group evaluated the 
PD patients. We employed the following five clinical scales. (1) The Unified Parkinson‟s Disease Rating 
Scale (UPDRS) was used for rating patients‟ mood and cognition (UPDRS1), the activities of daily living 
(UPDRS2),  motor  symptoms  (UPDRS3),  and  the  complications  of  the  therapy  (UPDRS4).  (2)  The 
Parkinson‟s Disease Quality of Life Scale (PDQ39) measured the QoL by summoning the scores of its 
eight  subscales  (mobility,  activities  of  daily  living,  emotional  well-being,  stigma,  social  support, 
cognition, communication, and bodily discomfort). (3) The Epworth Sleepiness Scale (measuring the level 
of daytime drowsiness) and (4) the Hamilton Depression Rating Scale (measuring the level of depression) 
were also used for rating nonmotor symptoms. (5) The Schwab and England Scale was used to assess the 
degree  of  functional  independence  in  daily  living.  We  employed  several  clinical  scales  because  we 
wanted to assess the overall QoL of patients from different points of view.  
The ratings of all scales were always carried out in their dopaminergic “ON” state. We assessed it by 
asking each patient and his relatives (1) “What is the amount of the first morning dose that normally 
allows him/her to reach the best control of symptoms?” and (2) “How long does it take to reach the „ON‟ Modugno et al.: Theater, Rehabilitation, and Parkinson’s Disease  TheScientificWorldJOURNAL (2010) 10, 2301–2313 
 
 
 
2304 
state?” As a result, patients were rated 30–60 min after the administration of a dose of L-dopa ranging 
from 100 to 200 mg.  
Physiotherapy 
Physiotherapy consisted of individual 2- to 3-h daily sessions, 3 days/week (~18 h/month), for 3 years, 
with  two  physiotherapists.  Aims  of  this  therapy  were:  preventing  osteoarticular  rigidity,  muscular 
contractures,  and  atrophies;  grading  postural  abnormalities;  promoting  postural  reactions;  promoting 
postural changes; training balance and gait; and increasing tolerance to the physical exercise (for more 
details see Table 1).  
TABLE 1 
Exercises Included in the Physiotherapy Rehabilitation Program 
Activities  Basic Exercises* 
Cardiovascular warm up (10 min)  Intersegmental coordination exercises 
Exercises to release shoulder and pelvic girdle 
Pelvic anteversion and retroversion movements to stimulate diaphragmatic 
respiration (supine position) 
Breathing exercises to promote expansion of the chest 
Stretching exercises (15 min)  Exercises to stretch the muscles of the posterior kinematic chain 
Exercises to stretch the pectoralis muscles 
Exercises to stretch the ischio-cruralis muscles 
Assumption of the prone position, sitting on heels and stretching the arms out in 
front 
Exercises to stretch lumbar muscles (in the supine position, each knee, in turn, is 
brought to the chest) 
Postural exercises (15 min)  Anterior and lateral flexion, extension and rotation of the trunk in standing position, 
to promote spinal column mobilization  
Overground gait training (20 min)  Overground gait training (forwards, backwards, and lateral) 
Walking on the spot 
Balance training (15 min)  Path with obstacles 
Balance exercises performed in order of difficulty: 
Heel-to-toe walking 
Lateral walking, crossing the legs 
Walking along a path on surfaces of different texture (foam mats, mats containing 
sand, etc.) 
Relaxation exercises (15 min)  Intersegmental coordination exercises  
Segmental passive mobilization (until maximum joint range of motion is reached) 
Breathing exercises to promote expansion of the chest 
*  Depending on the single patient’s motor and functional status, the physiotherapist could include exercises other 
than those indicated as basic exercises. 
Therapeutic Theater Workshop 
The theatrical workshop, led by the theater company, consisted of 6-h daily sessions, for two consecutive 
days, once or twice per month, for a total of ~18 h/months, for 3 years (for more details see Table 2). The Modugno et al.: Theater, Rehabilitation, and Parkinson’s Disease  TheScientificWorldJOURNAL (2010) 10, 2301–2313 
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initial part of every workshop focused on exercising basic skills. All subjects were trained in controlling 
breathing, posture, gait, coordination, and manual tasks.  
(MOVIE S1: This movie shows some exercises of motor coordination performed by one PD patient, 
with 1 year of theater training, together with an actress during one theatrical workshop session. The 
patient was in “ON” therapy.) 
TABLE 2 
Exercises Included in a Typical Theater Training Session 
Activities  Basic Exercises* 
Vocal warm up (20 min)  Feet on the ground, erect position on the chairs 
Massage and tapping of the chest 
Hands on the belly, movement of abdominal muscles 
Diaphragmatic breathing 
Vocal emission of the consonant “S” 
Vocal emission of the consonant “M”, keeping mouth closed 
Vocal emission of the syllable “NO”, low note, insisting on the projection of the 
consonant as a springboard for the vowel 
Emission of the syllables PA, PE, PI, PO, PU 
Emission of the consonant “M”, keeping mouth closed, but gradually rising note and 
back 
Emission of the syllable “MA”, but gradually rising note and back 
Vocal emission of the breath, freely moving the facemask 
Rotation of the tongue inside and outside of teeth 
Emission of the vowels keeping the tongue out of the mouth 
Emission of the vowels, exasperating facial expression 
Emission of all the vowels while laughing 
Preparation of the scene 
(40 min): to be 
performed in a circle, 
always repeating the 
same line to the person 
beside them 
Slow vocal articulation of a line from the scene 
Projection of the line into the distance, leaning the sound on the consonant 
Articulation of the line in a low voice 
Repeating the line with a different rhythm 
Attempt to speak the line in five different emotional moods (anger, fear, sensuality, 
happiness, sadness) 
In circle, adding the second line to the first 
Attempt to speak the two lines in five different moods (see above) 
Continue the same exercise, adding lines of the script depending on the scene 
Staging (5 h)  After having created an acting and an audience area, the involved patients perform 
the scene they were previously exercising technically  
*  Some lessons could be preceded by a video (10 min) of the scene to be performed. 
The patients were then taught to approach theater texts and to analyze them. In the second part of the 
workshop,  patients  rehearsed  singly  or  in  groups,  together  with  actors,  based  on  improvisation  or 
sketches. Sketches were always directed by actors of the company with the aim of recreating on the stage 
behaviors and emotions that could occur in real life. Through this training, patients learned to express 
themselves and to communicate with each other both verbally and nonverbally. After periods of training, 
some of the patients wrote a script and eventually presented it with the help of the director.  Modugno et al.: Theater, Rehabilitation, and Parkinson’s Disease  TheScientificWorldJOURNAL (2010) 10, 2301–2313 
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(MOVIE  S2:  This  movie  shows  a  sketch  where  a  PD  patient,  with  1  year  of  theater  training, 
impersonates a man who finds out that he has won the lottery. The patient was in “ON” therapy.) 
Statistics 
We employed the Shapiro-Wilk test of normality in order to assess whether a given sample came from a 
normally distributed population.  
Analyses of variance (ANOVAs) were employed for assessing (1) changes in drug therapy at T0 vs. 
T3 in theater vs. control group and (2) changes over time (T0, T1, T2, T3) in theater vs. control groups 
across all clinical scales. Mauchley‟s test evaluated the sphericity assumption and, where appropriate, 
correction  of  the  degrees  of  freedom  was  made  according  to  the  Greenhouse-Geisser  procedure. 
Bonferroni correction was applied to all posthoc tests (pairwise comparisons).  
In order to control for the sample size, for each statistic we computed the partial eta-squared (η
2), a 
coefficient that estimates the so-called “effect size”. The effect size is a measure used for describing the 
degree of relationship between dependent and independent variables, independently from the sample size. 
Values of η
2 higher than 0.14 indicate strong effect sizes, namely that the F values obtained are unlikely 
to depend on the sample size. Values of η
2 smaller than 0.06 indicate small effect sizes. 
RESULTS  
At time T0, i.e., prior to the theatrical experience, all clinical parameters of the two groups (see Table 3) 
were homogeneous. T-tests revealed no significant differences for age (t[18] = 0.618, p = 0.544), years 
with  diagnosis  (t[18]  =  –0.047,  p  =  0.963),  or  Hoehn  and  Yahr  score  (t[18]  =  0.361,  p  =  0.722). 
Furthermore, an ANOVA on the amount of L-dopa equivalents/kg administered, with time (T0 and T3) 
and group (theater and control) as factors, showed a significant main effect of time (two-way repeated-
measures ANOVA F[1] = 6.564, p < 0.05), but no main effect of group (F[1] = 0.582, p = 0.455) and of 
interaction (F[1] = 3.1, p = 0.09). However, even though there was no interaction between time and group 
(it was very close to be significant), theater-group patients did not require an increase in dopaminergic 
drug therapy during the course of the study, while the control patients did.  
TABLE 3 
Clinical Data of Patients Affected by PD of Control (CTRL) and Theater (TH) Group*  
Patient 
Sex  Age  Hoehn & Yahr 
T0 
Years with 
Diagnosis 
L-DOPA EQ. 
T0 
L-DOPA EQ. 
T3 
CTRL  TH  CTRL  TH  CTRL  TH  CTRL  TH  CTRL  TH  CTRL  TH 
1  F  F  70  58  4  3  16  24  3650  905  3800  977 
2  M  M  64  58  4  4  12  7  3400  1603  3600  1403 
3  F  F  65  61  4  4  13  6  1105  977  1141  877 
4  F  F  62  72  4  4  9  12  805  3400  705  3400 
5  M  M  59  65  3  3  5  8  200  1263  344  1263 
6  M  M  63  66  4  4  10  11  3350  1563  3600  1707 
7  F  F  65  62  3  3  6  5  561  1263  661  1263 
8  M  M  65  63  3  3  9  10  1105  1543  1255  1507 
9  M  M  62  61  3  4  6  4  1363  566  1363  766 
10  F  F  57  54  3  2  8  8  1263  441  1407  561 Modugno et al.: Theater, Rehabilitation, and Parkinson’s Disease  TheScientificWorldJOURNAL (2010) 10, 2301–2313 
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Mean (SEM)  63.2 
(1.13) 
62 
(1.58) 
3.5 
(0.17) 
3 
(0.22) 
9.4 
(1.1) 
10 
(1.8) 
1680.3 
(405.1) 
1352.4 
(261.2) 
1787.6 
(423.8) 
1372 
(251.5) 
t-test  p = 0.544  p = 0.722  p = 0.963  See Results (ANOVA) 
*  For each patient, sex, age, Hoehn and Yahr scores (indicating the relative level of disability due to PD disease) 
at  time  point  T0  in  the  phase  “OFF”  (after  the  suspension  of  anti-Parkinson  therapy  for  12  h),  years  with 
diagnosis, L-dopa equivalents/kg at time T0, and L-dopa equivalents/kg at time T3 are given. At the bottom of the 
table, the p values for the comparisons between the two groups are reported. 
In order to compare the scores obtained in the clinical scales by the two groups, first we checked 
whether data were normally distributed. Results are reported in Table 4. As can be noted in the large 
majority of instances (107/120 or 89.2%), the Shapiro-Wilk test was not significant, indicating that the 
assumption  of  normality  could  not  be  refused.  Thus,  we  decided  to  apply  parametric  rather  than 
nonparametric statistics because the former are much more robust.  
TABLE 4 
Results of Shapiro-Wilk Test of Normality Obtained for the Two Groups of PD Patients (Control 
Group and Theater Group) in all Clinical Scales (and Subscales) at the Four Time Points*  
  Control (p Values)  Theater (p Values) 
T0  T1  T2  T3  T0  T1  T2  T3 
Epworth Sleepiness   = 0.481  = 0.331  = 0.263  = 0.517  = 0.643  = 0.305  = 0.680  = 0.892 
Hamilton  = 0.692  = 0.251  = 0.198  = 0.101  = 0.078  = 0.837  = 0.630  < 0.01 
Schwab and England  = 0.287  = 0.191  = 0.389  < 0.05  = 0.321  < 0.05  = 0.124  < 0.05 
UPDRS1  = 0.247  = 0.295  = 0.636  = 0.576  = 0.140  = 0.496  = 0.392  = 0.258 
UPDRS2  = 0.299  = 0.481  = 0.554  = 0.887  = 0.618  = 0.728  = 0.769  = 0.882 
UPDRS3   = 0.737  = 0.759  = 0.574  = 0.505  = 0.161  < 0.05  = 0.099  < 0.05 
UPDRS4  = 0.683  = 0.252  = 0.073  = 0.084  = 0.321  = 0.417  = 0.750  = 0.569 
Mobility**  = 0.144  = 0.126  = 0.307  = 0.257  = 0.866  = 0.252  = 0.999  = 0.197 
Activities of daily living**  = 0.883  = 0.601  = 0.101  = 0.238  = 0.071  = 0.183  = 0.241  = 0.458 
Emotional well-being**  = 0.137  = 0.198  = 0.519  < 0.01  = 0.447  = 0.259  = 0.415  = 0.092 
Stigma**  = 0.186  = 0.528  = 0.457  < 0.05  = 0.767  = 0.321  = 0.344  = 0.550 
Social support**  = 0.245  = 0.158  = 0.191  = 0.272  < 0.05  = 0.717  < 0.05  = 0.108 
Cognition**  = 0.627  = 0.073  = 0.516  = 0.113  = 0.106  = 0.555  = 0.072  < 0.05 
Communication**  = 0.295  = 0.198  = 0.138  = 0.532  = 0.053  = 0.140  = 0.156  < 0.05 
Bodily discomfort**  = 0.099  = 0.092  = 0.344  < 0.01  = 0.241  = 0.272  = 0.062  = 0.191 
*  The Shapiro-Wilk test tests the null hypothesis that a given sample came from a normally distributed population. 
Thus, p values less than 0.05 indicate  that the data are not from a normally distributed population and are 
indicated in bold.  
**  PDQ39 subscales. 
The effect of theatrical training is illustrated in Tables 5 and 6, Figs. 1 and 2. To assess differences for 
the score of each clinical scale, we employed a doubly multivariate repeated-measures design with time 
(T0, T1, T2, T3) and group (control, theater) as factors. Results are summarized in Table 6.  
(MOVIE  S3:  This  movie  shows  a  PD  patient  performing  a  singing  exercise  at  time  T0  [at  the 
beginning of theatrical workshop] and at time T1 [after 1 year of theater training]. Clearly, at T0, the Modugno et al.: Theater, Rehabilitation, and Parkinson’s Disease  TheScientificWorldJOURNAL (2010) 10, 2301–2313 
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patient is impaired, while at T1, he is able to perform the exercise without effort. In both instances, the 
patient was in “ON” therapy.)  
(MOVIE S4: This movie shows two sketches played by a PD patient at T1 [after 1 year of theatrical 
training] and at T3 [after 3 years of theatrical training]. In the first sketch, the patient [who is in front of 
the camera, wearing a black T-shirt] is acting the part of a man who is altercating with two other people 
[another  PD  patient  and  an  actress].  In  the  second  sketch,  the  same  patient  [wearing  a  black  shirt] 
performs some karate moves, leading the group choreography. It is worth noticing: [1] the much greater 
mobility and body control; [2] the increased expressivity; [3] the remarkable weight loss of the patient in 
the second sketch with respect to the first one. In both instances, the patient was in “ON” therapy.)  
TABLE 5 
Mean Scores and Standard Error Mean Obtained by the Two Groups of PD Patients (Control 
Group and Theater Group) in the Five Clinical Scales (and Subscales) at the Four Time Points  
  Control  Theater 
T0  T1  T2  T3  T0  T1  T2  T3 
Epworth Sleepiness   9.9 ± 0.74  9.2 ± 0.87  9 ± 1.17  9.6 ± 1.08  11 ± 0.83  7 ± 0.97  6 ± 1.13  4 ± 0.86 
Hamilton  16.8 ± 1.96  18.7 ± 2.49  18.3 ± 2.44  17.7 ± 2.50  24 ± 1.23  19.6 ± 1.53  16.1 ± 1.55  11.7 ± 1.12 
Schwab and England  67 ± 3.00  72 ± 3.27  72 ± 3.89  75 ± 5.22  62 ± 4.90  66 ± 4.00  74 ± 3.71  79 ± 3.79 
UPDRS1  4.1 ± 0.84  4.3 ± 0.88  4.4 ± 0.91  4.3 ± 0.91  2.3 ± 0.50  2.5 ± 0.62  1.9 ± 0.41  1.5 ± 0.34 
UPDRS2  16.6 ± 2.03  15.5 ± 1.93  15.7 ± 2.02  15.6 ± 2.10  14.6 ± 2.58  14.6 ± 2.67  13.7 ± 2.33  13.3 ± 2.31 
UPDRS3   23.5 ± 3.01  22.1 ± 3.04  22.6 ± 3.29  21.7 ± 3.33  26.9 ± 4.86  23.4 ± 5.29  21.2 ± 4.30  19.5 ± 4.03 
UPDRS4  5.9 ± 0.95  6.2 ± 1.24  6.8 ± 1.37  7.2 ± 1.54  7.4 ± 0.69  7.2 ± 1.02  6.7 ± 1.01  6.5 ± 1.12 
Mobility*  11.1 ± 1.43  10.6 ± 1.25  9.4 ± 1.23  9.3 ± 1.45  11.7 ± 1.58  11.6 ± 1.43  9.2 ± 1.28  7.6 ± 1.07 
Activities of daily living*  7.1 ± 0.60  6.3 ± 0.72  6.0 ± 0.77  5.7 ± 1.01  8.4 ± 1.49  7.9 ± 1.20  6.6 ± 0.45  4.7 ± 0.68 
Emotional well-being*  6.6 ± 0.78  5.8 ± 0.93  5.7 ± 0.86  5.2 ± 0.80  7.7 ± 0.99  7.0 ± 0.77  5.8 ± 0.90  3.9 ± 0.85 
Stigma*  3.3 ± 0.56  3.1 ± 0.60  3.1 ± 0.53  3.2 ± 0.66  3.1 ± 0.67  3.2 ± 0.49  2.0 ± 0.42  2.0 ± 0.39 
Social support*  3.6 ± 0.31  3.0 ± 0.45  2.8 ± 0.33  2.5 ± 0.54  6.2 ± 0.66  4.6 ± 0.64  3.6 ± 0.52  2.4 ± 0.37 
Cognition*  4.7 ± 0.52  4.0 ± 0.52  3.7 ± 0.58  3.6 ± 0.69  5.7 ± 0.56  5.4 ± 0.62  4.7 ± 0.63  3.6 ± 0.43 
Communication*  3.1 ± 0.50  2.4 ± 0.43  2.7 ± 0.47  2.4 ± 0.52  4.2 ± 0.63  4.3 ± 0.50  3.8 ± 0.49  2.9 ± 0.23 
Bodily discomfort*  4.2 ± 0.55  3.1 ± 0.46  3.0 ± 0.42  2.9 ± 0.48  5.3 ± 0.68  5.0 ± 0.71  3.6 ± 0.48  2.8 ± 0.33 
*  PDQ39 subscales. 
TABLE 6 
Results of the Doubly Multivariate Repeated-Measures ANOVA with Group (Control, Theater) and 
Time (T0, T1, T2, T3) as Factors in the Clinical Scales (or Subscales) 
  Time  Group  Time  Group 
F (df)  Sig.*   η
2  F (df)  Sig.*   η
2  F (df)  Sig.*   η
2 
Epworth Sleepiness   F(1.5,28.1) = 27.28  < 0.001  0.603  F(1,18) = 3.47  = 0.07  0.162  F(1.5,28.1) = 19.99  < 0.001  0.526 
Hamilton  F(3,54) = 40.3  < 0.001  0.691  F(1,18) = 0.00  = 0.99  0.000  F(3,54) = 50.81  < 0.001  0.738 
Schwab and England  F(2.1,38.7) = 21  < 0.001  0.538  F(1,18) = 0.55  = 0.81  0.003  F(2.1,38.7) = 4.55  < 0.05  0.202 
UPDRS1  F(1.9,35.9) = 2.62  = 0.09  0.127  F(1,18) = 5.15  < 0.05  0.222  F(1.9,35.9) = 3.97  < 0.05  0.181 
UPDRS2  F(2.1,37.1) = 3.35  < 0.05  0.157  F(1,18) = 0.32  = 0.57  0.018  F(2.1,37.1) = 1.28  = 0.29  0.067 
UPDRS3  F(1.8,33.3) = 8.24  < 0.01  0.314  F(1,18) = 0.00  = 0.95  0.000  F(1.8,33.3) = 3.62  < 0.05  0.168 
UPDRS4  F(1.4,25.2) = 0.11  = 0.82  0.006  F(1,18) = 0.07  = 0.78  0.004  F(1.4,25.2) = 3.88  < 0.05  0.177 
Mobility**  F(1.3,24.6) = 11.77  < 0.001  0.395  F(1,18) = 0.02  = 0.96  0.000  F(1.3,24.6) = 2.07  = 0.15  0.103 
Activities of daily living**  F(1.3,23.9) = 8.46  < 0.01  0.320  F(1,18) = 0.3  = 0.58  0.017  F(1.3,23.9) = 2.36  = 0.13  0.116 
Emotional well-being**  F(1.9,35.7) = 15.48  < 0.001  0.462  F(1,18) = 0.6  = 0.81  0.003  F(1.9,35.7) = 4.3  < 0.05  0.193 
Stigma**  F(3,54) = 3.18  < 0.05  0.150  F(1,18) = 0.73  = 0.40  0.039  F(3,54) = 2.76  < 0.05  0.133 Modugno et al.: Theater, Rehabilitation, and Parkinson’s Disease  TheScientificWorldJOURNAL (2010) 10, 2301–2313 
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Social support**  F(3,54) = 22.59  < 0.001  0.557  F(1,18) = 4.35  = 0.051  0.195  F(3,54) = 6.97  < 0.001  0.279 
Cognition**  F(1.9,35.7) = 9.93  < 0.001  0.356  F(1,18) = 1.40  = 0.25  0.073  F(1.9,35.7) = 1.88  = 0.16  0.095 
Communication**  F(1.8,33.3) = 4.46  < 0.05  0.199  F(1,18) = 3.79  = 0.07  0.174  F(1.8,33.3) = 2.09  = 0.14  0.104 
Bodily discomfort**  F(1.6,29.6) = 13.73  < 0.001  0.433  F(1,18) = 1.88  = 0.19  0.095  F(1.6,29.6) = 3.44  = 0.052  0.162 
*  p values. 
**  PDQ39 subscales.  
η
2 represents the partial eta-squared, values higher than 0.14 indicate strong effect sizes; namely, that the F values obtained are 
unlikely to depend on the sample size (see Materials and Methods).  
 
FIGURE 1. Mean scores and standard error of the means at the four time 
points  in  the  Epworth  Sleepiness  Scale  (A),  Hamilton  Depression  Rating 
Scale (B), Schwab and England Scale (C), and in the four subscales of the 
UPDRS  (D).  All  values  are  reported  as  percentage  with  respect  to  the Modugno et al.: Theater, Rehabilitation, and Parkinson’s Disease  TheScientificWorldJOURNAL (2010) 10, 2301–2313 
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maximum of the scale. Patients were tested in the “ON” state (see Material 
and Methods for more details). 
We found a significant main effect of the factor time in all clinical scales except for UPDRS1 and 
UPDRS4. This indicates that in the majority of the scales, a significant change occurred at some point 
during the 3 years of the study. Posthoc pairwise comparisons showed that the mean scores of nonmotor 
clinical scales tended to change early on; namely, often they were already different after the first year (T0 
vs. T1), while the improvement was less fast for UPDRS3, in which the first significant difference could 
be observed after the second year.  
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FIGURE 2. Mean scores and standard error of the means at the four time 
points for the theater (gray bars) and control group (black bars) in the eight 
subscales of the PDQ39. All values are reported as percentage with respect 
to the maximum of the scale. Patients were tested in the “ON” state (see 
Material and Methods for more details). 
The factor group was significant only for the UPDRS1 scale. Posthoc pairwise comparisons on the 
factor group revealed that the mean differences between scores of the control and theater groups became 
significantly different at T2 and T3 only. This means that at T0 and T1, there was not a significant 
difference in patients‟ mood and cognition between the two groups. 
Finally a significant interaction was found in the Epworth Sleepiness Scale, Hamilton Depression 
Rating  Scales,  Schwab  and  England  Scale,  UPDRS1,  UPDRS3,  and  UPDRS4  scales,  and  for  three 
subscales of PDQ39 (emotional well-being, stigma, and social support). Posthoc pairwise comparisons 
revealed that (1) PD theater patients showed a significant improvement in most of the nonmotor clinical 
scales and, to a lesser extent, in the UPDRS3; on the other hand, the scores of the control group remained 
substantially unchanged; (2) in the theater group, the improvement in nonmotor clinical scales took place 
faster than those in the motor scale, which became evident only after 2 years.  
Remarkably, with one only exception, the η
2 was always higher than 0.14 when the F values were 
significant (see Table 6). This finding underlines that in all those instances, there were strong effect sizes; 
namely, that the F values obtained did not depend on the small sample size.  
To summarize, at T0, the cognitive status of the two groups was homogeneous (at T0 the UPDRS1, 
the  PDQ39  emotional  well-being,  and the PDQ39  stigma  were  not significantly  different). The  only 
significant difference was related to the feeling of social support; patients of the theater group felt less 
supported than controls. Nonmotor symptoms of PD patients of the theater group improved over time 
more consistently than motor symptoms. Of relevance, they showed a very quick improvement in the 
mood, quality of sleep, and perception of social support (as revealed by the significant improvement of 
the Hamilton Depression Rating Scale, Epworth Sleepiness Scale, and PDQ39 social support scale scores 
at  T1  with  respect  to  T0).  All  these  parameters  further  improved  at  T2.  In  addition,  significant 
ameliorations of functional independence, emotional well-being, and stigma were assessed at the same 
time. Finally, at T2, motor symptoms also significantly improved. Thus, our results show that the theater 
group  had  a  clear  improvement  over  time,  while  the  control  group  did  not  display  significant 
improvements during the 3 years with respect to T0. 
DISCUSSION  
The idea of PD as a pure motor disturbance must be reconsidered. Phenomena like kinesia paradoxica, 
i.e., the sudden mobility and agility of otherwise akinetic PD patients in situations of great emergency, 
suggest that the nature of this pathology cannot be motor in a strict sense. In line with this hypothesis, 
Mazzoni et al.[14] showed that patients can exhibit “normal” motor behavior even in simple arm-reaching 
movements, not just in extreme cases. Clinical observations of PD progression also reveal the negative 
effects of nonmotor symptoms on patient well-being[15]. Often a patient‟s personality traits change: calm 
and quiet people, after developing PD, can start doing things they never did before, such as writing or 
painting compulsively[16,17]. Patients might even lose the ability to estimate the consequences of their 
actions correctly, developing compulsive reward-seeking activities (e.g., gambling[18]). About 50% of 
PD patients suffer from apathy or anhedonia[19], which leads to loss of motivation and ability to plan 
daily life.  
Despite  this  evidence,  nonmotor  features  are  usually  under-recognized  and  undertreated  because 
attention is paid to motor symptoms that are treated with dopaminergic drugs. This approach can lead to 
the  paradoxical  discrepancy  between  an  objectively  good  control  of  motor  disturbances  and  an Modugno et al.: Theater, Rehabilitation, and Parkinson’s Disease  TheScientificWorldJOURNAL (2010) 10, 2301–2313 
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increasingly negative feeling of well-being reported by the patient. Thus, to achieve global improvement 
in personal well-being, complementary approaches are needed, but only a few have been explored.  
Even  though  physiotherapy  has  been  shown  to  be  effective  in  improving  patients‟  physical 
performance and QoL[20], benefits are often temporary[7,8]. Occupational therapies, art therapies (such 
as music[11] and dance[10]), and group psychotherapy[9] have also been shown to produce positive 
effects  on  QoL,  anxiety,  and  depression.  However,  at  the  moment,  it  is  not  possible  to  formulate 
recommendations for those approaches because there is too few evidence of positive effects. For instance, 
Pacchetti et al.[11] showed that active music therapy improves both motor abilities and the emotional 
status of PD patients; however, improvements tended to disappear within a few months after completion 
of the therapy.  
On the other hand, our study shows for the first time that active theater has positive and stable effects 
on the cognitive, affective, and motor domains of PD patients, thus improving their overall QoL. The 
greater impact of our theater training with respect to previously employed complementary therapies could 
be explained in two ways that are likely to interact with each other. First, our rehabilitation program had a 
longer duration than previous programs (i.e., the active music therapy of Pacchetti et al.[11] lasted only 3 
months). Second, theater requires the development of peculiar abilities. To perform on stage, patients are 
forced to control their movements, thoughts, and emotions carefully. Furthermore, theater requires a high 
degree  of  personal  interaction  and  thus  promotes  socialization,  lessening  the  feeling  of  isolation 
frequently reported by PD patients. Possibly, thanks to all these elements, active theater deeply motivates 
patients, allowing them to regain self-confidence and to develop higher self-control.  
LIMITATIONS OF THE STUDY 
We are aware of methodological limitations of our study and, on this basis, we believe that it has to be 
considered a pilot study. First of all, the sample is relatively small (but the low number of subjects was 
needed  in  order  to  allow  a  rigorous  intervention  on  each  subject  for  a  long  period  of  time  and  we 
controlled that our results did not depend on the small sample size). Second, as stated in the Materials and 
Methods section, we carried out this experiment only on patients affected by a moderate form of PD 
(Hoehn & Yahr stage 2–4). The rationale was that since mild PD patients have less motor symptoms, they 
could fully live the theatrical experience and we thus thought it would be simpler to observe differences 
with respect to the control group. Currently, we do not know whether the most severe cases of PD could 
benefit by the theatrical experience. This will be the topic of future researches. Third, we are aware that 
our theater therapy program might not be easily transferred to different hospitals or clinics.  
Nevertheless, this first quantitative demonstration of the efficacy of active theater as a rehabilitative 
tool for PD could open the doors to other clinical trials and confirm that the use of complementary 
approaches  can  bridge  the  gap  between  the  best  effect  of  the  pharmacological  therapy  and  the 
achievement of a better QoL. 
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